Senetek Einführung von Invicorp in Neuseeland - 500 Beiträge pro Seite

[Huges]

Laut folgender Pressemitteilung führt Senetek in Zusammenarbeit mit Douglas Pharmaceutical das Potenzmittel Invicorp ein.

http://biz.yahoo.com/prnews/040616/law008_1.html

[Huges]

SENETEK PLC ANNOUNCES NEW ZEALAND LAUNCH
OF INVICORP® BY DOUGLAS PHARMACEUTICALS

NAPA, California, June 16, 2004 -- Senetek PLC (NASDAQ: SNTK - News), www.senetekplc.com, a healthcare technologies company focused on developing and co-marketing products for the anti-aging markets worldwide, today announced that commercial sales of Senetek`s patented erectile dysfunction drug Invicorp® by its commercial partner, Aukland-based Douglas Pharmaceuticals Limited, will commence June 28. The launch involves both Invicorp I and Invicorp II, the dosages also approved in Denmark nationally and as the Reference State for pan-European approval under the Mutual Recognition Procedure. The product will be sold in a proprietary, user-friendly kit containing a pre-filled ampoule, syringe, 21 gauge needle for filling and a super-fine 30 gauge needle for administration, developed by Senetek for use worldwide. Final marketing approval was received from Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, on May 25. Under the Development and Distribution Agreement signed with Douglas in 2002, Senetek will receive 50% of Douglas` net sales of the product.

Frank J. Massino, Chairman and Chief Executive Officer of Senetek, commented, "Invicorp has met with great professional acceptance and patient loyalty in England where it is prescribed on a named patient basis, but New Zealand is the first market in which it will be commercially available. Invicorp is ideally suited for men suffering from severe erectile dysfunction or receiving treatments for such conditions as diabetes or hypertension for whom other ED medications are contra-indicated. The Decision Resources 2002 study projected that Invicorp could gain an 80% share of the world market in the injectable/transurethral ED treatment category currently served by Pharmacia`s Caverject®, Schwartz Pharma`s Edex® and Vivus` Muse®, and we believe this is a first small step toward making that a reality."

Mr. Graeme Douglas, Chief Executive of Douglas Pharmaceuticals Limited, said, "We at Douglas Pharmaceuticals are delighted to launch Invicorp in New Zealand. The Medsafe approval represents a significant milestone for the product. With that achieved, the challenge of commercialization begins. We are certain that Invicorp will become the leading injectable treatment for erectile dysfunction in New Zealand."

* * * *

Senetek is a life sciences-driven product development and licensing company focused on the high growth market for dermatological and skin care products primarily addressing photodamage and age-related skin conditions. Senetek`s patented compound Kinetin is a naturally occurring cytokinin that has proven effective in improving the appearance of aging skin with virtually none of the side effects associated with acid-based active ingredients. Senetek has licensed Kinetin to leading global and regional dermatological and skin care marketers including Valeant Pharmaceuticals, The Body Shop and Revlon, and recently announced the grant to Valeant Pharmaceuticals of rights to license Zeatin, a promising analogue of Kinetin currently in pre-clinical trials. Senetek`s researchers at the University of Aarhus, Denmark, also are collaborating with the Institute of Experimental Botany, Prague, and with Beiersdorf AG, Hamburg, to identify and evaluate additional new biologically active compounds for this high growth field.

Visit Senetek PLC`s Web site at http://www.senetekplc.com.

Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: [e-mail]

[Umckaloabo]

Da warten die Aktionäre 2 Jahre auf die Einführung des Produktes und dann ist es soweit und die Aktie fällt.
Das ist Senetek.

[fuchspruefer]

Da geht es endlich mit Invicorp in Europa los - und Senetek fällt.
Mir fällt dazu nichts mehr ein.
Es ist schon so,dass das Management Schrott ist, wie auch omoos schon oft geklagt hat.

[Umckaloabo]

Ardana deal to take Senetek to market in Europe

ALASTAIR REED


ARDANA, the Edinburgh-based reproductive health specialist, has signed a "strategically significant" deal with a US biotech to manufacture and market its patented erectile dysfunction treatment.

In its first major deal since it launched Striant, its own testosterone replacement drug, Ardana said it had agreed an exclusive deal with Nasdaq-listed Senetek to bring its Invicorp drug to European markets.

The Scottish company will be fully responsible for taking Invicorp through the European regulatory process, as well as for seeking national marketing approval.

Dr Maureen Lindsay, who replaced Simon Best as chief executive earlier this month, said: "While it’s far too early to say how much this deal is worth, it is extremely significant strategically. The real value is the enormous synergy with Striant, as well as our current portfolio of other drugs."

Under the terms of the deal, Ardana will pay royalties to Senetek based on net sales, as well as for reaching "cumulative net sales targets". Senetek will also receive "milestone payments" as regulatory hurdles are cleared.

Senetek chairman Frank Massino described Ardana as "perfectly suited" to give Invicorp the "focus it deserves", adding that the Scottish group had the "technical expertise and financial capability to speed it to market".

The non-oral erectile dysfunction market is estimated to be worth $85 million worldwide and $45m in Europe, and Lindsay said she believed the demand for injectable treatments would increase "as awareness of the condition increases".

Invicorp will be commercially available in New Zealand later this month, having passed the necessary regulatory hurdles. It is also in the process of being approved in Denmark.

Ardana has long been viewed as one of Scotland’s leading biotech stars, and with the recovery of an appetite for new issues, it has increasingly been linked with a flotation. However Lindsay said: "We are studying the window - or cat flap - of opportunity, but are still really keeping our options open. Any decision could still be between nine and 18 months away."